Search research articles
Contact Us
Filters
Showing results (221-230 of 312) with videos related to
Page
of 32
Sort By:
Cancer Chemotherapy and Pharmacology
|
March 23, 2021
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)
Fred Saad, Kim N Chi, Neal D Shore, et al.
The New England Journal of Medicine
|
May 30, 2020
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
Cora N Sternberg, Karim Fizazi, Fred Saad, et al.
The Journal of Urology
|
October 22, 2020
Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical Data
E David Crawford, Jason M Hafron, Scott T Tagawa, et al.
The Oncologist
|
November 30, 2017
Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program
Oliver Sartor, Nicholas J Vogelzang, Christopher Sweeney, et al.
European Urology
|
March 12, 2016
Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer
Karim Fizazi, Kim N Chi, Johann S de Bono, et al.
Oncology and Therapy
|
April 17, 2025
On the Horizon: A Global Multidisciplinary Perspective on Delivering Emerging Therapies for Patients with BCG-Naïve High-Risk NMIBC
Bernadett E Szabados, Félix Guerrero-Ramos, Enrique Grande, et al.
European Urology
|
April 21, 2024
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study
Fred Saad, Maha H A Hussain, Bertrand Tombal, et al.
JAMA Network Open
|
May 7, 2025
Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer: A Secondary Analysis of the ARCHES Randomized Clinical Trial
Arun A Azad, Daniel P Petrylak, Taro Iguchi, et al.
The Journal of Urology
|
August 7, 2023
Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS)
Sandip M Prasad, William C Huang, Neal D Shore, et al.
The Prostate
|
March 3, 2022
Hereditary cancer risk assessment and genetic testing in the community urology practice setting
Neal D Shore, Lauren Lenz, Elizabeth S Cogan, et al.
Page
of 32
Search research articles
Search
Showing results (221-230 of 312) with videos related to
Sort By:
Page
of 32
Cancer Chemotherapy and Pharmacology
|
March 23, 2021
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)
Fred Saad, Kim N Chi, Neal D Shore, et al.
The New England Journal of Medicine
|
May 30, 2020
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
Cora N Sternberg, Karim Fizazi, Fred Saad, et al.
The Journal of Urology
|
October 22, 2020
Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical Data
E David Crawford, Jason M Hafron, Scott T Tagawa, et al.
The Oncologist
|
November 30, 2017
Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program
Oliver Sartor, Nicholas J Vogelzang, Christopher Sweeney, et al.
European Urology
|
March 12, 2016
Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer
Karim Fizazi, Kim N Chi, Johann S de Bono, et al.
Oncology and Therapy
|
April 17, 2025
On the Horizon: A Global Multidisciplinary Perspective on Delivering Emerging Therapies for Patients with BCG-Naïve High-Risk NMIBC
Bernadett E Szabados, Félix Guerrero-Ramos, Enrique Grande, et al.
European Urology
|
April 21, 2024
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study
Fred Saad, Maha H A Hussain, Bertrand Tombal, et al.
JAMA Network Open
|
May 7, 2025
Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer: A Secondary Analysis of the ARCHES Randomized Clinical Trial
Arun A Azad, Daniel P Petrylak, Taro Iguchi, et al.
The Journal of Urology
|
August 7, 2023
Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS)
Sandip M Prasad, William C Huang, Neal D Shore, et al.
The Prostate
|
March 3, 2022
Hereditary cancer risk assessment and genetic testing in the community urology practice setting
Neal D Shore, Lauren Lenz, Elizabeth S Cogan, et al.
Page
of 32